Novartis at ESMO
Sep 17, 2020
Novartis 2020 ESMO Annual Meeting Virtual Portal
We are boldly reimagining cancer and blood disorders.
Press releases
- Novartis announces new survival data for its treatment for advanced breast cancer with a specific mutation will be presented at the ESMO Virtual Congress 2020
- Novartis reports late-breaking data from Phase III study in advanced melanoma
- Novartis announces its advanced breast cancer treatment receives highest rating of any CDK4/6 inhibitor on the ESMO Magnitude of Clinical Benefit Scale